China approves its first homegrown COVID drug
Subscribe to keep reading.
Sign up to stay briefed on what the Chinese government is doing, thinking, and saying.
Already a subscriber? Log in.
On Wednesday, a piece of good news emerged on the COVID-fighting front:
China’s drug regulator (NMPA) granted emergency approval of a COVID-19 treatment drug co-developed by Brii Biosciences, Tsinghua University, and the Third People’s Hospital of Shenzhen.
We’ll spare you the technical detai...
Your subscription doesn't include access to this content. Upgrade your account to access.